TrialThe Lancet. Infectious diseases2022

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.

ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.